Literature DB >> 15739097

Cartilage oligomeric matrix protein in serum in systemic lupus erythematosus and knee osteoarthritis. Preliminary communication.

M Wisłowska1, B Jabłońska.   

Abstract

The cartilage oligomeric matrix protein (COMP) is a glycoprotein, which occurs mainly in an articular cartilage. The amount of this protein increases under the influence of cytokines and growth factors. As a result of various diseases that cause damage to cartilage, fragments of matrix protein are released into synovial fluid and then into blood. The assessment of matrix protein level in serum, for example COMP, permits the establishment of the degree of cartilage damage in inflammatory joint diseases, and permits observation of the effectiveness of the treatment. Blood was collected from 30 systemic lupus erythematosus (SLE) patients, and from 30 patients with knee osteoarthritis (OA) who constituted the control group. Serum COMP level was determined using an inhibition enzyme-linked immunosorbent assay (ELISA). The average value of the serum COMP level in SLE patients was 11.3+/-3.7 U/l. According to correlation coefficients, serum COMP level is independent of patients' age, disease duration and the clinical picture of SLE. No correlation was found between serum COMP level and bone mass density (BMD) changes. In SLE patients with decreased haemoglobin levels (<11.0 g/dl) values compared with patients with normal haemoglobin level, the serum COMP level was observed to be significantly higher (P<0.05). Both in SLE patients with erythrocyte sedimentation rate (ESR) values over 60 mm/h and in patients with ESR values below 60 mm/h, the serum COMP level was observed to be significantly higher (P<0.05). A significant positive correlation was found between serum COMP level and ESR value, as well as a number of thrombocytes. Negative correlation occurred between the serum COMP level and the value of haemoglobin. The average value of COMP in OA patients was 10.4+/-2.7 U/l. No correlation was found between serum COMP level and patients' age and disease duration. There was correlation between the serum COMP level and the T-score value of densitometry examinations in OA patients. No statistical differences were found between the average serum COMP levels for SLE and OA patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15739097     DOI: 10.1007/s00296-004-0581-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  19 in total

Review 1.  Structure and biology of cartilage and bone matrix noncollagenous macromolecules.

Authors:  D Heinegård; A Oldberg
Journal:  FASEB J       Date:  1989-07       Impact factor: 5.191

2.  Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays.

Authors:  W Emlen; L O'Neill
Journal:  Arthritis Rheum       Date:  1997-09

Review 3.  Classification of disease: osteoarthritis.

Authors:  R D Altman
Journal:  Semin Arthritis Rheum       Date:  1991-06       Impact factor: 5.532

4.  Bone scan and serum markers of bone and cartilage in patients with knee pain and osteoarthritis.

Authors:  I F Petersson; T Boegård; J Dahlström; B Svensson; D Heinegård; T Saxne
Journal:  Osteoarthritis Cartilage       Date:  1998-01       Impact factor: 6.576

5.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

6.  HLA DRB1* typing and cartilage oligomeric matrix protein (COMP) as predictors of joint destruction in recent-onset rheumatoid arthritis.

Authors:  F A Wollheim; K B Eberhardt; U Johnson; T Saxne
Journal:  Br J Rheumatol       Date:  1997-08

7.  Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet.

Authors:  E Fex; K Eberhardt; T Saxne
Journal:  Br J Rheumatol       Date:  1997-11

8.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

9.  Cartilage oligomeric matrix protein and thrombospondin 1. Purification from articular cartilage, electron microscopic structure, and chondrocyte binding.

Authors:  P E DiCesare; M Mörgelin; K Mann; M Paulsson
Journal:  Eur J Biochem       Date:  1994-08-01

10.  Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism.

Authors:  B Månsson; D Carey; M Alini; M Ionescu; L C Rosenberg; A R Poole; D Heinegård; T Saxne
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more
  3 in total

1.  Ultrasonographic evaluation of the femoral cartilage thickness in patients with systemic lupus erythematosus.

Authors:  Arif Kaya; Murat Kara; Tülay Tiftik; Mehmet Engin Tezcan; Mehmet Akif Öztürk; Ayşen Akıncı; Levent Özçakar
Journal:  Rheumatol Int       Date:  2012-07-21       Impact factor: 2.631

2.  Cartilage oligomeric matrix protein participates in the pathogenesis of liver fibrosis.

Authors:  Fernando Magdaleno; Elena Arriazu; Marina Ruiz de Galarreta; Yu Chen; Xiaodong Ge; Laura Conde de la Rosa; Natalia Nieto
Journal:  J Hepatol       Date:  2016-06-15       Impact factor: 25.083

3.  Cartilage oligomeric matrix protein in idiopathic pulmonary fibrosis.

Authors:  Louis J Vuga; Jadranka Milosevic; Kusum Pandit; Ahmi Ben-Yehudah; Yanxia Chu; Thomas Richards; Joshua Sciurba; Michael Myerburg; Yingze Zhang; Anil V Parwani; Kevin F Gibson; Naftali Kaminski
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.